

### **CLAIM AMENDMENTS**

This listing of claims will replace all prior versions,, and listings, of claims in the application.

Listing of claims:

1-100 (canceled)

101. (currently amended) An immunoconjugate that comprises an antibody joined to a therapeutic agent, wherein the antibody comprises an immunoglobulin or antigen-binding fragment thereof that competitively inhibits binding of the monoclonal antibody BR96, as produced by the hybridoma deposited with the ATCC and assigned Accession No. HB10036, to a carcinoma cell, and further wherein the antibody comprises a human Fc region.

102. (previously presented) The immunoconjugate of claim 101, wherein the antibody is a monoclonal antibody or a fragment of a monoclonal antibody.

103. (canceled)

104. (previously presented) The immunoconjugate of claim 101, wherein the antibody is a bifunctional antibody with a binding specificity for two different antigens.

105. (previously presented) The immunoconjugate of claim 101, wherein the antibody is a chimeric antibody.

106. (previously presented) The immunoconjugate of claim 101, wherein the antibody is a humanized antibody.

107. (canceled)

108. (canceled)

109. (previously presented) The immunoconjugate of claim 101 wherein the therapeutic agent is selected from the group consisting of a cytotoxin, an anti-tumor drug, a radioactive agent, a second antibody, and an enzyme.

110. (previously presented) The immunoconjugate of claim 109, wherein the therapeutic agent is a cytotoxin that is a ribosome binding toxin.

111. (previously presented) The immunoconjugate of claim 110, wherein the ribosome binding toxin is ricin A.

112. (previously presented) The immunoconjugate of claim 110, wherein the therapeutic agent is an exotoxin.

113. (previously presented): The immunoconjugate of claim 112, wherein the exotoxin is Pseudomonas exotoxin A.

114. (previously presented) The immunoconjugate of claim 112, wherein the exotoxin is truncated to remove the cell-binding domain.

115. (previously presented) The immunoconjugate of claim 112, wherein the amino terminus of the exotoxin has been modified to include a lysine amino acid residue.

116. (previously presented) The immunoconjugate of claim 109 which is purified.

117.-119. (canceled)

120. (currently amended) The immunoconjugate of any one of claims 101, 102, and 104-106 ~~101-106 and 119~~, wherein the therapeutic agent is a pro-drug converting enzyme.

121. (currently amended) The immunoconjugate of any one of claims 101, 102, and 104-106 ~~101-106 and 119~~, wherein the therapeutic agent is a drug.

122. (currently amended) The immunoconjugate of any one of claims 101, 102, and 104-106 ~~101-106 and 119~~ which is purified.

123. (currently amended) A pharmaceutical composition comprising a pharmaceutically effective amount of the immunoconjugate of any one of claims 101, 102, and 104-106 ~~101-106 and 119~~, and a pharmaceutically acceptable carrier.

124. (previously presented) The pharmaceutical composition of claim 123, wherein the immunoconjugate is purified.

125. (previously presented) A pharmaceutical composition comprising a pharmaceutically effective amount of the immunoconjugate of claim 121, and a pharmaceutically acceptable carrier.

126. (previously presented) The pharmaceutical composition of claim 125, wherein the immunoconjugate is purified.

127. (previously presented) A pharmaceutical composition comprising a pharmaceutically effective amount of the immunoconjugate of claim 122, and a pharmaceutically acceptable carrier.

128. (canceled)